Daewoong Pharmaceuticals Co., Ltd pursues meaningful work by collaborating with great people, working with autonomy, and choosing opportunities that create shared value for the company, customers, and society. Above all, we are committed to driving real change and innovation through what we do. Establish in 1945, Daewoong Pharmaceuticals is a leading healthcare company in Korea that has achieved consecutive successes in new drug development through constant challenge and innovation. Today, we continue to expand a diverse pipeline and next-generation platform technologies, aiming to develop first-in-class and best-in-class innovative medicines for patients worldwide. Our commitment to global standards is proven by GMP certifications from major regulatory authorities such as the U.S. FDA and EMA, along with ISO certifications that demonstrate our excellence in quality, environmental management, and occupational health and safety systems. At Daewoong, we believe that the growth of our employees fuels the growth of the company. We foster a forward-looking corporate culture by promoting smart work practices, career development, and global talent training programs. Beyond Korea, we strive to become a global healthcare leader by creating new value for healthier lives and better quality of life worldwide.
我們正在追蹤 Daewoong Pharmaceutical 的市場擴張
過去 90 日內有 92 個訊號。
Daewoong Pharmaceutical 的國際擴張與競爭對手的比較
Daewoong Pharmaceutical你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Daewoong Pharmaceutical你 | 0 | 0 | — | 0 | 0 |
Senior Partnership & Leasing - Bali
查看招聘Kuta, Bali, Indonesia · 5個月前
Chief Engineer - Bali
查看招聘Kuta, Bali, Indonesia · 5個月前
Cafe Team
查看招聘Kuta, Bali, Indonesia · 6個月前
#News 📢 대웅제약 presented integrated model-based research findings on its SGLT-2 inhibitor #Enavogliflozin, at the 2026 PAGE (PAGE - Population Approach Group Europe) conference, a leading European forum in quantitative pharmacology.This study quantitatively elucidated the causal relationship between increased urinary glucose excretion following drug administration and the reduction in glycated hemoglobin (HbA1c), and scientifically demonstrated that the absence of significant pharmacokinetic diff ...
已結束Not all long-acting depot platforms are created equal. The key lies in how efficiently a drug can be delivered — in a smaller volume.In Episode 2 of the "Maximizing Therapeutic Potential with CURE®" series, we explore how CURE® achieves industry-leading drug loading to deliver a once-monthly therapeutic dose with up to 4–5× less depot mass than competing platforms.#Daewoong #GLP1 #CURE #platform #obesity #diseases #longactinginjectables ...
已結束Small differences in wording can easily lead to misunderstandings in pharmaceutical communication.✍️👩💻Ji Young Yoon from 대웅제약’s Medical Team took on the challenge of bringing clarity to the confusion surrounding UDCA-related scientific messages, which had been spreading across multiple channels during the pandemic. By restructuring the messaging system, she helped ensure that accurate, evidence-based information could be delivered consistently.Curious about her journey? Watch the full video no ...
進行中大熊製藥今年數字醫療銷售目標3000億韓元，推出整合人工智能醫療平台，計劃全國遠程健康監測。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Daewoong Pharmaceutical 業務、市場及增長訊號的快速解答。
